CLINICAL AND PARACLINICAL FEATURES OF CORONARY ARTERY ANEURYSMS IN KAWASAKI DISEASE
##plugins.themes.vojs.article.main##
Tóm tắt
Objectives: To describe clinical and subclinical features according to level of coronary artery
aneurysm (CAA) in Kawasaki disease. Patients and methods: 545 patiens with Kawasaki disease at Cardiovascular Center - Vietnam National Children’s Hospital between January 2019 and June 2022. Results: Patients were classifi ed as 4 groups: no involvement, small aneurysm, medium aneurysm, large or giant aneurysm (GAA). The rates of 4 groups were: 44.6%, 19.4%, 18.2%, 7%. The average age at diagnosis of 12.6 months, 49.4% under 12 months, the ratio of male: female approximates 1.5:1, 11.7% had atypical Kawasaki disease with lowest in no involvement group and highets in GAA group. Day at diagnosis, day of IVIG, total fever duration, IVIG-nonresponsive, the leucocyte
count pre-IVIG, CRP pre-IVIG, platelets post-IVIG increased gradually with levels of CAA, but hemoglobin pre-IVIG, albumin decreased with
levels of CAA, statistically signifi cant diff erences between four groups (p<0.05). Conclusion: In the subacute phage, there is
a high rate of CAA. It had higher duration of diagnosis, Resistance to IVIG , leucocyte count, CRP and lower albumin, hemoglobin, age with another groups. The infl ammatory response status increases with the level of CAA. There are statistically signifi cant diff erences in some clinical and labotory variables in four groups.
##plugins.themes.vojs.article.details##
Từ khóa
Kawasaki disease, level of coronary artery aneurysm
Tài liệu tham khảo
disease in the United States and worldwide.
Progress in Pediatric Cardiology. 1997; 6(3):
181-185.
2. Newburger JW, Takahashi M, Gerber MA,
et al. Diagnosis, treatment, and long-term
management of Kawasaki disease: a statement
or health professionals from the Committee
on Rheumatic Fever, Endocarditis and Kawasaki
Disease, Council on Cardiovascular Disease in the
Young, American Heart Association. Circulation.
2004; 110(17): 2747-2771.
3. McCrindle BW, Rowley AH, Newburger
JW, et al. Diagnosis, Treatment, and Long - Term
Management of Kawasaki Disease: A Scientifi c
Statement for Health Professionals From the
American Heart Association. Circulation. 2017;
135(17).
4. Descriptive Epidemiology of Kawasaki
Disease in Japan, 2011–2012: From the Results
of the 22nd Nationwide Survey. Accessed August
21, 2022.
5. Kim: Assessment of risk factors for Korean
children with Kawasaki disease.
6. Lee J, Kim GB, Kwon BS, et al. Two Cases of
Super-Giant Coronary Aneurysms after Kawasaki
Disease. Korean Circ J. 2014; 44(1): 54-58.
7. Garrido-García L, Moran E, YamazakiNakashimada M, et
al. Giant coronary artery aneurysms complicating Kawasaki disease in
Mexican children. Cardiology in the young. 2017;
28: 1-5.
8. Dietz SM, Kuipers IM, Tacke CEA, et al. Giant
aneurysms: A gender-specifi c complication of
Kawasaki disease? Journal of Cardiology. 2017;
70(4): 359-365.
9. Pham Thao Nguyen. Features of coronary
artery aneurysm in patients with Kawasaki
non-responsive to immunoglobulin transfusion.
10. Onouchi: A genome-wide association
study identifi es three new risk loci for Kawasaki
disease.
11. Chen: Coronary artery complication in
Kawasaki disease and the importance of early
interventaion: a system review and meta-analysis.
12. McCrindle BW, Manlhiot C, Newburger JW,
et al. Medium‐Term Complications Associated
With Coronary Artery Aneurysms After Kawasaki
Disease: A Study From the International Kawasaki
Disease Registry. J Am Heart Assoc. 2020; 9(15):
e016440.
13. Masuzawa Y, Mori M, Hara T,et al. Elevated
d-Dimer Level is a Risk Factor for Coronary
Artery Lesions Accompanying Intravenous
mmunoglobulin - Unresponsive Kawasaki
Disease. Therapeutic Apheresis and Dialysis.
2015; 19(2): 171-177.